9.80
price up icon4.70%   0.44
pre-market  プレマーケット:  9.53   -0.27   -2.76%
loading
前日終値:
$9.36
開ける:
$9.47
24時間の取引高:
737.79K
Relative Volume:
1.27
時価総額:
$519.08M
収益:
$8.78M
当期純損益:
$-104.70M
株価収益率:
-4.135
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
+12.90%
1か月 パフォーマンス:
-16.10%
6か月 パフォーマンス:
-27.84%
1年 パフォーマンス:
+98.78%
1日の値動き範囲:
Value
$9.30
$9.815
1週間の範囲:
Value
$8.8113
$9.815
52週間の値動き範囲:
Value
$4.09
$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
名前
Stoke Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
781-430-8200
Name
住所
45 WIGGINS AVENUE, BEDFORD, MA
Name
職員
110
Name
Twitter
@stoketx
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
STOK's Discussions on Twitter

STOK を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
STOK
Stoke Therapeutics Inc
9.80 519.08M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-20 開始されました Chardan Capital Markets Buy
2024-10-14 再開されました Leerink Partners Outperform
2024-03-26 アップグレード TD Cowen Market Perform → Outperform
2023-11-20 再開されました JP Morgan Neutral
2023-07-25 ダウングレード TD Cowen Outperform → Market Perform
2023-05-01 アップグレード BofA Securities Underperform → Neutral
2023-04-26 再開されました Canaccord Genuity Buy
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2022-10-24 アップグレード SVB Leerink Mkt Perform → Outperform
2022-01-31 開始されました Jefferies Buy
2021-12-03 開始されました BofA Securities Buy
2021-11-22 アップグレード JP Morgan Neutral → Overweight
2021-05-18 開始されました UBS Neutral
2021-05-10 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-02-10 ダウングレード Wedbush Outperform → Neutral
2020-12-15 再開されました H.C. Wainwright Buy
2020-12-11 繰り返されました Needham Buy
2020-10-23 開始されました Cantor Fitzgerald Overweight
2020-09-29 再開されました JP Morgan Neutral
2020-09-29 開始されました Needham Buy
2019-12-18 開始されました Wedbush Outperform
2019-11-12 開始されました BTIG Research Buy
2019-10-25 開始されました H.C. Wainwright Buy
2019-07-15 開始されました Canaccord Genuity Buy
2019-07-15 開始されました Cowen Outperform
2019-07-15 開始されました Credit Suisse Outperform
2019-07-15 開始されました JP Morgan Overweight
すべてを表示

Stoke Therapeutics Inc (STOK) 最新ニュース

pulisher
Jan 20, 2025

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

When the Price of (STOK) Talks, People Listen - Stock Traders Daily

Jan 19, 2025
pulisher
Jan 18, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat

Jan 18, 2025
pulisher
Jan 15, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register

Jan 14, 2025
pulisher
Jan 11, 2025

Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World

Jan 11, 2025
pulisher
Jan 11, 2025

Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register

Jan 10, 2025
pulisher
Jan 10, 2025

Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Learn to Evaluate (STOK) using the Charts - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 08, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada

Jan 08, 2025
pulisher
Jan 08, 2025

Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance

Jan 08, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks

Jan 07, 2025
pulisher
Jan 07, 2025

STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics aligns with regulators on Dravet study - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire

Jan 07, 2025
pulisher
Jan 06, 2025

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire

Jan 06, 2025
pulisher
Jan 06, 2025

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Stoke Therapeutics Advances First Disease-Modifying Dravet Syndrome Treatment to Phase 3 - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Jan 01, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat

Dec 31, 2024
pulisher
Dec 29, 2024

When (STOK) Moves Investors should Listen - Stock Traders Daily

Dec 29, 2024
pulisher
Dec 27, 2024

Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com

Dec 27, 2024
pulisher
Dec 27, 2024

Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada

Dec 27, 2024
pulisher
Dec 26, 2024

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance

Dec 26, 2024
pulisher
Dec 24, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat

Dec 24, 2024
pulisher
Dec 24, 2024

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street Corp - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

State Street Corp Grows Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Dec 24, 2024
pulisher
Dec 22, 2024

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – What’s Next? - Defense World

Dec 22, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

(STOK) Proactive Strategies - Stock Traders Daily

Dec 19, 2024
pulisher
Dec 18, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth - Yahoo Finance

Dec 17, 2024

Stoke Therapeutics Inc (STOK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):